WO2004005473A3 - Hcv fusion proteins with modified ns3 domains - Google Patents

Hcv fusion proteins with modified ns3 domains Download PDF

Info

Publication number
WO2004005473A3
WO2004005473A3 PCT/US2003/020996 US0320996W WO2004005473A3 WO 2004005473 A3 WO2004005473 A3 WO 2004005473A3 US 0320996 W US0320996 W US 0320996W WO 2004005473 A3 WO2004005473 A3 WO 2004005473A3
Authority
WO
WIPO (PCT)
Prior art keywords
hcv
fusion proteins
domains
modified
cells
Prior art date
Application number
PCT/US2003/020996
Other languages
French (fr)
Other versions
WO2004005473A2 (en
Inventor
Michael Houghton
Original Assignee
Chiron Corp
Michael Houghton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp, Michael Houghton filed Critical Chiron Corp
Priority to AU2003248818A priority Critical patent/AU2003248818A1/en
Priority to CA002491508A priority patent/CA2491508A1/en
Priority to JP2004519849A priority patent/JP2005532064A/en
Priority to EP03763172A priority patent/EP1539809A4/en
Publication of WO2004005473A2 publication Critical patent/WO2004005473A2/en
Publication of WO2004005473A3 publication Critical patent/WO2004005473A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The invention provides HCV fusion proteins that include a mutated NS3 protease domain, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4+ and CD8+ T cells. The method can be used in model systems to develop HCV-specific immunogenic compositions, as well as to immunize a mammal against HCV.
PCT/US2003/020996 2002-07-02 2003-07-02 Hcv fusion proteins with modified ns3 domains WO2004005473A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2003248818A AU2003248818A1 (en) 2002-07-02 2003-07-02 Hcv fusion proteins with modified ns3 domains
CA002491508A CA2491508A1 (en) 2002-07-02 2003-07-02 Hcv fusion proteins with modified ns3 domains
JP2004519849A JP2005532064A (en) 2002-07-02 2003-07-02 HCV fusion protein with modified NS3 domain
EP03763172A EP1539809A4 (en) 2002-07-02 2003-07-02 Hcv fusion proteins with modified ns3 domains

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39369402P 2002-07-02 2002-07-02
US60/393,694 2002-07-02
US39451002P 2002-07-08 2002-07-08
US60/394,510 2002-07-08

Publications (2)

Publication Number Publication Date
WO2004005473A2 WO2004005473A2 (en) 2004-01-15
WO2004005473A3 true WO2004005473A3 (en) 2004-04-01

Family

ID=30118384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020996 WO2004005473A2 (en) 2002-07-02 2003-07-02 Hcv fusion proteins with modified ns3 domains

Country Status (8)

Country Link
EP (1) EP1539809A4 (en)
JP (2) JP2005532064A (en)
CN (1) CN1678630A (en)
AU (1) AU2003248818A1 (en)
CA (1) CA2491508A1 (en)
PL (1) PL374349A1 (en)
RU (1) RU2005102484A (en)
WO (1) WO2004005473A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491808B2 (en) * 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
WO2004039950A2 (en) * 2002-10-25 2004-05-13 Chiron Corporation Activation of hcv-specific cells
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP1765386A4 (en) * 2004-05-17 2008-07-30 Novartis Vaccines & Diagnostic Truncated hepatitis c virus ns5 domain and fusion proteins comprising same
US7871625B2 (en) 2004-08-27 2011-01-18 Novartis Vaccines And Diagnostics, Inc. HCV multiple epitope fusion antigens with modified proteolytic cleavage sites and uses thereof
AU2005295317B2 (en) * 2004-10-18 2011-10-13 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
AU2011254055B2 (en) * 2004-10-18 2012-12-20 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
US7968697B2 (en) * 2005-05-25 2011-06-28 Chrontech Pharma Ab Hepatitis C virus non-structural NS3/4A fusion gene
WO2007041861A1 (en) * 2005-10-13 2007-04-19 Virexx Medical Corp. Chimeric antigen containing hepatitis c virus polypeptide and fc fragment for eliciting an immune response
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
ATE539079T1 (en) 2006-03-23 2012-01-15 Novartis Ag IMIDAZOCHINOXALINE COMPOUNDS AS IMMUNE MODULATORS
EP2061888A2 (en) * 2006-08-25 2009-05-27 Novartis AG Hcv fusion polypeptides
WO2010033841A1 (en) 2008-09-19 2010-03-25 Globeimmune, Inc. Immunotherapy for chronic hepatitis c virus infection
US9321847B2 (en) 2010-09-20 2016-04-26 Ramot At Tel Aviv University Ltd. Activatable toxin complexes comprising a cleavable inhibitory peptide
US10267803B2 (en) * 2015-03-27 2019-04-23 Ortho-Clinical Diagnostics, Inc. HCV NS4A/modified NS3 polypeptides and uses thereof
CN106749672B (en) * 2016-11-18 2020-06-30 江西农业大学 Hepatitis C virus fusion antigen protein and application thereof
CN111153963B (en) * 2020-01-19 2021-08-10 华南理工大学 Anti-inflammatory pentapeptide, extraction and separation method thereof and application of anti-inflammatory pentapeptide in memory improvement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038360A2 (en) * 1999-11-24 2001-05-31 Chiron Corporation Novel hcv non-structural polypeptide
WO2001090812A1 (en) * 2000-05-23 2001-11-29 Massachusetts Institute Of Technology Ultraviolet fluoride nonlinear devices

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69433971T2 (en) * 1993-11-04 2005-09-08 Innogenetics N.V. Of human T-cells immunodominant epitopes of the virus of C-hepatitis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001038360A2 (en) * 1999-11-24 2001-05-31 Chiron Corporation Novel hcv non-structural polypeptide
WO2001090812A1 (en) * 2000-05-23 2001-11-29 Massachusetts Institute Of Technology Ultraviolet fluoride nonlinear devices

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DIEPOLDER H.M. ET AL.: "Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection", J. OF VIROLOGY, vol. 71, no. 8, August 1997 (1997-08-01), pages 6011 - 6019, XP002179125 *
ECKART M.R. ET AL.: "The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 192, no. 2, 30 April 1993 (1993-04-30), pages 399 - 406, XP000577111 *
GRAKOUI A. ET AL.: "Characterization of the Hepatitis C virus-encoded serie proteinase: Determination of proteinase-dependent polyprotein cleavage sites", JOURNAL OF VIROLOGY, vol. 67, no. 5, May 1993 (1993-05-01), pages 2832 - 2843, XP002111520 *
See also references of EP1539809A4 *
SHOJI I. ET AL.: "Proteolytic activity of NS3 serine proteinase of hepatitis C virus efficiently expressed in escherichia coli", HEPATOLOGY, vol. 22, no. 65, December 1995 (1995-12-01), pages 1648 - 1655, XP002973752 *
TOMEI L. ET AL.: "NS3 is a serine protease required for processing of hepatitis C virus polyprotein", JOURNAL OF VIROLOGY, vol. 67, no. 7, July 1993 (1993-07-01), pages 4017 - 4026, XP000561255 *

Also Published As

Publication number Publication date
EP1539809A4 (en) 2006-03-08
CN1678630A (en) 2005-10-05
CA2491508A1 (en) 2004-01-15
RU2005102484A (en) 2006-01-20
EP1539809A2 (en) 2005-06-15
JP2005532064A (en) 2005-10-27
AU2003248818A1 (en) 2004-01-23
PL374349A1 (en) 2005-10-17
WO2004005473A2 (en) 2004-01-15
JP2006265267A (en) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2004005473A3 (en) Hcv fusion proteins with modified ns3 domains
WO2005113837A3 (en) Truncated hepatitis c virus ns5 domain and fusion proteins comprising same
CA2389206A1 (en) Activation of hcv-specific t cells
EP1230347B1 (en) Method for the preparation of purified hcv rna by exosome separation
TW200732346A (en) Chimeric hepatitis C virus antigens for eliciting an immune response
WO2003024480A3 (en) In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
AU6616301A (en) Modification of hepatitis b core antigen
SG165155A1 (en) Novel flavivirus antigens
PL345018A1 (en) Particles of hcv envelope proteins: use for vaccination
Lin et al. Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and gpE2 and nonstructural proteins 3, 4, and 5
HK1038573A1 (en) Method to identify agents active against hcv by using the structure coordinates of hepatitis c virus protease
WO2004111082A3 (en) Compound containing polyprotein ns3/ns4 and hcv polypeptide ns5b, expression vectors comprising corresponding nucleic sequences and the therapeutic application thereof
NZ518999A (en) Vaccine compositions
EP1930416A4 (en) Novel recombinant human hepatitis c virus-like particle and method for producing the same
Naderi et al. Hepatitis C virus and vaccine development
CA2390082A1 (en) Novel hcv non-structural polypeptide
AU5649998A (en) Epitopes of the protein pre-m/m of the dengue virus, synthetic peptides
WO2008024518A3 (en) Hcv fusion polypeptides
Kim et al. Towards defining a minimal functional domain for NTPase and RNA helicase activities of the hepatitis C virus NS3 protein
EP1799868A4 (en) Hcv non-structural protein mutants and uses thereof
WO2003102165A3 (en) IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
GB9810756D0 (en) Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
DK1334197T3 (en) Yeast-derived vaccine against IPNV
DK1506222T3 (en) Chimeric human papillomavirus16 L1 proteins comprising an L2 peptide, virus-like particles made therefrom, and a method for producing the particles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 374349

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 2491508

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004519849

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003248818

Country of ref document: AU

Ref document number: 537601

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003763172

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005102484

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 118/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 20038207192

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003763172

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003763172

Country of ref document: EP